Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

The company posted adjusted EPS of 63 cents, compared to 10 cents a year ago, beating the consensus of 47 cents. The U.S.

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Highlights,Welch Group LLC reduced its position in Pfizer,(NYSE:PFE),by over 35% in the fourth quarter.,Institutional ...

Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and its stock remained flat after market open. Pfizer reported $63.6 billion ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street ...

US pharmaceutical giant Pfizer Inc returned to profit in the fourth quarter from a loss in the same period of the previous ...

Spotify (NYSE: SPOT) stock surged 8.3% after the music streaming company reported fourth-quarter 2024 results that exceeded ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...